Mineralys Therapeutics, Inc. SEC filings MLYS

Mineralys Therapeutics, Inc. has 408 filings in SEC EDGAR's recent list, going back to Jun 13, 2022. Its latest annual report, Form ARS, was filed on Apr 10, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations, officer or director change). The company's fiscal year ends on December 31.

Mineralys Therapeutics, Inc. SEC filings
Form Description Filed Period
EFFECT Filing Apr 11, 2024 —
CORRESP Letter to the SEC Apr 9, 2024 —
UPLOAD Letter from the SEC Mar 26, 2024 —
SEC STAFF LETTER Filing Feb 15, 2023 —
EFFECT Filing Feb 9, 2023 —
CERT Filing Feb 9, 2023 —
CORRESP Letter to the SEC Feb 7, 2023 —
CORRESP Letter to the SEC Feb 7, 2023 —
8-A12B Filing Feb 6, 2023 —
DRSLTR Filing Dec 29, 2022 —
DRS/A Filing Dec 29, 2022 —
UPLOAD Letter from the SEC Dec 16, 2022 —
DRS/A Filing Dec 7, 2022 —
DRSLTR Filing Dec 6, 2022 —
SEC STAFF LETTER Filing Dec 1, 2022 —
UPLOAD Letter from the SEC Dec 1, 2022 —
DRS Filing Nov 4, 2022 —
D Filing Jun 13, 2022 —

Showing 18 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
MLYS (Nasdaq)
Fiscal year ends
December 31
Headquarters
Radnor, PA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1933414

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.